Suppr超能文献

皮肤黑色素瘤前哨淋巴结微转移的评估:与S-100蛋白和HMB-45相比,Melan-A和MART-1具有更高的诊断准确性。

Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45.

作者信息

Shidham V B, Qi D Y, Acker S, Kampalath B, Chang C C, George V, Komorowski R

机构信息

Medical College of Wisconsin, Department of Pathology, Milwaukee, Wisconsin 53226, USA.

出版信息

Am J Surg Pathol. 2001 Aug;25(8):1039-46. doi: 10.1097/00000478-200108000-00008.

Abstract

Accurate diagnosis of micrometastases in sentinel lymph nodes of cutaneous melanoma is critical for proper clinical management. S-100 protein and HMB-45 are the traditional immunomarkers widely used for this purpose. However, the interpretation of micrometastases by these markers is difficult with significant reduction in the diagnostic accuracy. S-100 protein demonstrates immunoreactivity for other nonmelanoma cells and obscures nuclear details, which are crucial for the interpretation of single cell metastases. We compared the new melanoma markers, Melan-A (clone A103) and MART-1 (clone M2-7C10), with S-100 protein and HMB-45, by examining 77 formalin-fixed paraffin-embedded sections of sentinel lymph nodes from 13 cases of primary cutaneous melanoma. CD68 (PG-M1) and hematoxylin-eosin-stained sections were also studied. Four pathologists interpreted the staining pattern after concealing the identity of each immunomarker. Az values (area under receiver operating characteristic curve) with receiver operating characteristic curve were higher with Melan-A (0.9742) and MART-1 (0.9779) compared with S-100 protein (0.8034) and HMB-45 (0.8651), demonstrating a higher diagnostic accuracy with Melan-A and MART-1 with superior detection of melanoma micrometastases. Melan-A and MART-1 showed sharp cytoplasmic immunoreactivity, almost exclusively restricted to the melanoma cells. Therefore, Melan-A and MART-1 are recommended for the evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma as a routine alternative to S-100 protein and HMB-45.

摘要

准确诊断皮肤黑色素瘤前哨淋巴结中的微转移对于正确的临床管理至关重要。S-100蛋白和HMB-45是广泛用于此目的的传统免疫标志物。然而,使用这些标志物对微转移进行解读存在困难,诊断准确性显著降低。S-100蛋白对其他非黑色素瘤细胞显示免疫反应性,并模糊了核细节,而核细节对于单细胞转移的解读至关重要。我们通过检查13例原发性皮肤黑色素瘤患者的77份福尔马林固定石蜡包埋的前哨淋巴结切片,将新的黑色素瘤标志物Melan-A(克隆A103)和MART-1(克隆M2-7C10)与S-100蛋白和HMB-45进行了比较。还研究了CD68(PG-M1)和苏木精-伊红染色切片。四名病理学家在隐匿每个免疫标志物的身份后对染色模式进行了解读。与S-100蛋白(0.8034)和HMB-45(0.8651)相比,Melan-A(0.9742)和MART-1(0.9779)的受试者工作特征曲线下面积(Az值)更高,表明Melan-A和MART-1具有更高的诊断准确性,对黑色素瘤微转移的检测更具优势。Melan-A和MART-1显示出强烈的细胞质免疫反应性,几乎完全局限于黑色素瘤细胞。因此,推荐使用Melan-A和MART-1评估皮肤黑色素瘤前哨淋巴结中的微转移,作为S-10蛋白和HMB-45的常规替代方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验